Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display Session

20P - IGN002 (antiCD20-IFNα2b) intravenously administered tumour targeted delivery of IFNα2b and its effects in non-Hodgkin lymphoma


01 Mar 2021


ePoster Display Session


Sribalaji Lakshmikanthan


Annals of Oncology (2021) 32 (suppl_1): S9-S13. 10.1016/annonc/annonc458


S. Lakshmikanthan1, P.S. Kolli1, M. Tugnait1, J. Dalsing-Hernandez2, D. Diaz2, P. Gonzales2, J.A. Barrett1

Author affiliations

  • 1 Preclinical Translational Medicine, Spectrum Pharmaceuticals, 92618 - Irvine/US
  • 2 Nonclinical Operations, Translational Drug Development, 85259 - Scottsdale/US

Abstract 20P


IFNα2b elicits potent anti-tumor antiproliferative and immunostimulatory activity; but with systemic toxicity. Delivering IFNα2b targeted to CD20+ lymphomas may lower systemic toxicity and increase therapeutic index. IGN002 is a novel recombinant protein comprised of anti-CD20 antibody (rituximab) fused to human IFNα2b by a peptide linker. Here, we report IGN002 stability in serum and tumor as well as efficacy in vivo in a B-cell non-Hodgkin lymphoma (NHL) xenograft model.


SCID mice bearing subcutaneous CD20+ tumors were administered i.v. rituximab at 10 mg/kg or IGN002 at 5, 10 or 15 mg/kg. Serum and tumors were collected at 1, 4, 24 or 48 hours (hrs) to assess IGN002 stability and tumor uptake using sandwich ELISA. In the same model, we examined tumor growth inhibition (TGI) and survival in mice treated with rituximab up to 5 mg/kg or IGN002 at doses up to 6 mg/kg.


IGN002 increased in serum in a dose-related manner with the peak levels achieved at 1-4 hrs (5mg/kg: 33±3; 10mg/kg: 155±5; 15mg/kg: 177±11 μg/ml) and a half-life of 24 hrs. At 48 hrs, IGN002 was still detectable in the circulation (5mg/kg: 25±2; 10mg/kg: 44±6; 15mg/kg: 45±3 μg/ml). Increases in IGN002 were also observed in the tumor at similar levels to rituximab. In the tumor, as hypothesized, IFNα2b increased in as dose-related manner with Cmax levels at 4 hrs of 41±12, 57±14 and 92±22 ng/mg of tumor tissue at 5, 10 and 15 mg/kg dose groups, respectively. At 48 hrs, IFNα2b levels were still detected (range: 18-38 ng/mg of tumor tissue). IGN002 improved survival at all doses investigated and increased inhibition of tumor growth when compared to rituximab with no adverse clinical signs.


IGN002 demonstrated adequate stability in the tumor resulting in the reduction in tumor mass and increased survival when compared to rituximab. Thus, demonstrating that the targeted delivery of IFNα2b to CD20+ tumor warrants further investigation in NHL patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Spectrum Pharmaceuticals.


Spectrum Pharmaceuticals.


S. Lakshmikanthan, P.S. Kolli, M. Tugnait, F. Lebel, J.A. Barrett: Shareholder/Stockholder/Stock options, Full/Part-time employment: Spectrum Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings